Share this article
Share this article
KNOXVILLE, Tenn. and NASHVILLE, Tenn., Jan. 15, 2021 /PRNewswire/ Lirio, the world leader in Precision Nudging, today announced it has earned Certified status for information security by HITRUST.
HITRUST CSF Certified status demonstrates that the organization s behavior change AI platform has met key regulations and industry-defined requirements and is appropriately managing risk. This achievement places Lirio in an elite group of organizations worldwide that have earned this certification. By including federal and state regulations, standards, and frameworks, and incorporating a risk-based approach, the HITRUST CSF helps organizations address these challenges through a comprehensive and flexible framework of prescriptive and scalable security controls.
AlloSource s ProChondrix CR, Cryopreserved Osteochondral Allograft, To Be Featured At The British Patellofemoral Society Meeting
News provided by
Share this article
Share this article
CENTENNIAL, Colo., Jan. 15, 2021 /PRNewswire/ AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue products, today announced its ProChondrix® CR allograft, will be featured in a presentation by Dr. David Argo at the British Patellofemoral Society Meeting, January 18-19, 2021. During the session titled
ProChondrix CR: Cryopreserved off-the-shelf Hyaline Cartilage Allograft. Dr. Argo, with Beacon Orthopaedics and Sports Medicine in Cincinnati, Ohio, will highlight his experience repairing osteochondral defects of the knee with AlloSource s allograft.
Share this article
Share this article
WILMINGTON, Del., Jan. 15, 2021 /PRNewswire/ The Center for the Biology of Chronic Disease (CBCD) announces an important discovery on the cause of Parkinson s diseases. The discovery shows how many common latent viruses, which infect the central and peripheral nervous systems, can cause Parkinson s disease (1). Latent viruses are hidden in the body in a way that most individuals don t know that they are infected. The discovery was published in the
Journal of NeuroVirology. More details are available at: https://pubmed.ncbi.nlm.nih.gov/33405201/.
Microcompetition Model: Book
The discovery was made possible by using the microcompetition model. The model uncovered new relationships between seemingly unrelated observations reported in the scientific literature. The discovery describes the molecular steps that lead from a latent infection to the clinical symptoms of Parkinson s disease. Many common viruses can cause the disease.
Share this article
Share this article
SUZHOU, China, Jan. 15, 2021 /PRNewswire/ Gracell Biotechnologies Inc. (NASDAQ: GRCL) ( Gracell ), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, has been granted the Medical Products Manufacturing Certificate (MPMC) from the Jiangsu Medical Products Administration (JSMPA, Jiangsu is a province/state in China) for its CAR-T cell therapy products. The certification was granted on January 4, 2021, and indicates that Gracell s site in Suzhou Industrial Park (SIP) has fully met the compliance requirements for Good Manufacturing Practice (GMP) in relation to the production of CAR-T cell therapy for cancer treatment.
Share this article
GOTHENBURG, Sweden, Jan. 15, 2021 /PRNewswire/
Isofol Medical AB (publ) ( Isofol ), (Nasdaq First North Premier Growth Market: ISOFOL) announces that a poster presentation is presented today at ASCO Gastrointestinal Cancers Symposium (ASCO-GI). The abstract present results from the Phase I/IIa ISO-CC-005 study which shows a correlation between clinical benefit and gene expression of the folate pathway in patients with metastatic colorectal cancer treated with 5-FU-based chemotherapy in combination with arfolitixorin. Furthermore, Isofol gives an update of the timing of the interim analysis in the global Phase III AGENT study.
In connection to ASCO-GI, Isofol together with QuartzBio, the Sahlgrenska Academy at University of Gothenburg and Sahlgrenska University Hospital, will present a poster with the title Folate pathway gene expression in metastatic colorectal cancer patients treated with arfolitixorin/5-FU-based chemotherapy on asco.org between 2.00 PM -